Fall 2018
AIPLA Chemical Practice Chronicles Newsletter
By Thomas L. Irving; Stacy D. Lewis*
Ex parte Gleave is a landmark decision to the extent PTAB approved a pharmaceutical composition claim under 35 USC §112(f), otherwise known as means-plus-function (MPF) claims.
35 USC §112(f) reads “an element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof.”
Section 112(f) provides a tool for patent applicants to, in a controlled way, literally cover equivalents by providing for literal infringement by structure, material, or acts that perform the same function. Historically MPF claims have been used in the mechanical and electrical/ computer fields. According to P.J. Federico’s 1952 commentary on the then-brand new 1952 Patent Act, life science MPF claims were contemplated from the birth of the statutory provision:
The last paragraph of section 112 relating to so-called functional claims is new. It provides that an element of a claim for a combination (and a combination may be not only a combination of mechanical elements, but also a combination of substances in a composition claim, or steps in a process claim) may be expressed as a means or step for performing a specified function, without the recital of structure, material or acts in support thereof.
For patent drafters practicing in the U.S. life sciences, the means-plus-function claim format may provide more accuracy and clarity than purely structural characterization and may end up providing broader scope. This alternative claim format is worth considering.
Click here to read the full article.
*Stacy Lewis is a law clerk at Finnegan
*Stacy Lewis is a Law Clerk at Finnegan
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Webinar
Building a Strong ADC Patent Portfolio – From Prosecution and Litigation Perspectives
May 15, 2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.